RJA
CARM

Raymond James & Associates’s Carisma Therapeutics CARM Stock Holding History

Raymond James & Associates’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-761
Closed -$70K – 4132
2021
Q2 		$70K Sell
761
-1,109
-59% -$70.7K ﹤0.01% 3884
2021
Q1 		$97K Buy
+1,870
New +$88.2K ﹤0.01% 3784

Other funds holding CARM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Raymond James & Associates's CARM Position: Q3 2021 in Review

Raymond James & Associates sold out of Carisma Therapeutics (CARM) in Q3 2021, closing a stake of 761 shares — an estimated $70K sold.

Raymond James & Associates first reported a position in CARM in Q1 2021 and held it in 2 quarters. The position peaked at $97K in Q1 2021. 103 funds tracked by Wall St. Rank hold CARM as of Q3 2021.

  • Raymond James & Associates reported no remaining Carisma Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Raymond James & Associates sold 761 Carisma Therapeutics shares in Q3 2021, an estimated $70K.
  • Raymond James & Associates first reported a position in Carisma Therapeutics in Q1 2021 and held it in 2 quarters.
  • Raymond James & Associates's Carisma Therapeutics position peaked at $97K in Q1 2021.
  • 103 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q3 2021.

Based on Raymond James & Associates's 13F filing for Q3 2021, filed 2 Nov 2021.